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Objective To study the activity of ﬁve different ﬂuoroquinolones against 22 epidemio-
logically related and unrelated strains of Staphylococcus aureus (13 methicillin-resistant
(MRSA) strains and nine methicillin-susceptible (MSSA) strains) in which the mechan-
isms of quinolone resistance are also investigated.
Methods The MICs of the different ﬂuoroquinolones were determined by the micro-
dilution method, in the presence and absence of reserpine. The quinolone resistance-
determining regions of the gyrA, gyrB, grlA and grlB genes were ampliﬁed and sequenced
to establish the presence of mutations. The molecular epidemiology of the 22 strains was
performed by low-frequency restriction analysis of chromosomal DNA with SmaI.
Results MSSA strains showed lower homology than MRSA strains, in which only two
clones were seen. Trovaﬂoxacin showed the best activity against these clinical isolates of
S. aureus, since strains carrying one amino acid change in both GyrA and GrlA subunits
remained susceptible to this antimicrobial agent. Furthermore, trovaﬂoxacin did not
seem to be a substrate for NorA.
Conclusion Trovaﬂoxacin was the most active quinolone tested against S. aureus strains,
followed by levoﬂoxacin and sparﬂoxacin, whereas ciproﬂoxacin and norﬂoxacin were
the least active quinolones, in both the presence and absence of reserpine. Epidemio-
logically related S. aureus strains presented different mechanisms of quinolone resistance,
suggesting a divergent evolution of the same clone. Finally, 16 S. aureus strains with a
ciproﬂoxacin plus reserpine MIC 1mg/L already showed a mutation in the grlA gene.
This MIC may be useful as a marker of mutation in this gene, contraindicating the use of
this quinolone, since a second mutation may develop during treatment.
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INTRODUCTION
Methicillin-susceptible (MSSA) and methicillin-
resistant Staphylococcus aureus (MRSA) are the
most frequently isolated Gram-positive bacteria
causing infection. Despite the availability of potent
antimicrobial agents and improved public health
conditions, S. aureus has remained a major human
pathogen which colonizes and infects both hospi-
talized patients with decreased host defenses and
healthy, immunologically competent people in the
community [1].
At the time of their introduction, ﬂuoroquino-
lones showed good activity against MSSA and
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MRSA [2]. Therefore, they were considered as
alternative therapy to treat infections caused by
MRSA [3,4]. However, the sporadic emergence of
quinolone resistance with the use of the new ﬂuor-
oquinolones has been reported [5,6] in S. aureus
isolated from the skin ﬂora of patients during
ciproﬂoxacin therapy as well as during the treat-
ment of MRSA carriers [7]. Thornsberry [8] found
that most of the MSSA strains were susceptible
(95.7%) or moderately susceptible (1.4%) to cipro-
ﬂoxacin, whereas 76.4% of the MRSA strains were
resistant to this antibiotic. The increase in cipro-
ﬂoxacin-resistant MRSA may be due to selective
pressure created not only by ciproﬂoxacin but also
by b-lactams, macrolides, lincosamides, chloram-
phenicol and aminoglycosides, since MRSA are
almost invariably multiresistant [9].
Fluoroquinolones act by inhibiting either DNA
gyrase and/or topoisomerase IV [10–12]. In S.
aureus, several reports have shown that topoisome-
rase IV is the primary target for quinolones [13,14].
The biochemical mechanisms of quinolone resis-
tance in S. aureus have been classiﬁed into two
groups: (1) mutations at the A subunit of the DNA
gyrase [15–19] and at the A subunit of the topoi-
somerase IV [13–15]; and (2) ﬂuoroquinolone
efﬂux in the cytoplasmatic membrane [20,21].
The described mutations of the gyrA gene, which
encodes the A subunit of DNA gyrase, related to
quinolone resistance, affect the amino acid codons
Ser84, Ser85 and Glu88 [15–19]. The quinolone
mutations in the grlA gene, encoding the A subunit
of topoisomerase IV, are located in the amino acid
codons Ser80, Glu84 and Ala116 [13–15]. Most of
these reports also showed amino acid substitu-
tions in the B subunits of the DNA gyrase and/
or the topoisomerase IV [14,17,18], encoded by the
gyrB and grlB genes, respectively, which have not
been directly associated with ﬂuoroquinolone
resistance.
NorA is one of the efﬂux systems related to
ﬂuoroquinolone resistance [20,21], and it seems
that the increase in the level of resistance provided
by NorA is due to overexpression of the gene
associated with a mutation in the promoter region
[22].
The main aim of this study was to determine the
activity of new ﬂuoroquinolones against epide-
miologically related and unrelated quinolone-
resistant strains of S. aureus (MRSA and MSSA),
in which the mechanisms of quinolone resistance
have been investigated in depth.
MATERIALS AND METHODS
Bacterial strains
In total, 22 clinical isolates of MSSA and MRSA
were randomly chosen from 249 strains isolated
during 1994 and 1995. The clinical isolates of S.
aureus were obtained from different samples sub-
mitted to the Clinical Microbiology Laboratory at
the Hospital Clinic of Barcelona, Spain. Nine
strains of 22 were methicillin susceptible, whereas
13 were resistant to this antimicrobial agent.
Susceptibility testing
Susceptibility testing was performed by a microdi-
lutionmethod for ciproﬂoxacin (Bayer, Leverkusen,
Germany), norﬂoxacin (Merck Sharp and Dohme,
WestPoint, Pa,USA), sparﬂoxacin (Rhone-Poulenc,
Vitry, France), levoﬂoxacin (Hoechst Marion Rous-
sell, Romainville, France) and trovaﬂoxacin (Pﬁzer
Ltd, Sandwich, UK), in accordance with the guide-
lines established by the National Committee for
Clinical Laboratory Standards (NCCLS) [23]. To
evaluate the action of the efﬂux systems, the MIC
of each antimicrobial agent was determined in the
presence and absence of 25mg/L of reserpine
(Sigma, St Louis, USA), an efﬂux pump inhibitor.
To determine the susceptibility to methicillin,
oxacillin was used as a marker. A strain was
considered resistant when the MIC was greater
than 4mg/L. In this case, the MICwas determined
by an agar dilution method, according to the
guidelines of the NCCLS [23].
Amplification of the quinolone resistance-
determining region (QRDR) of gyrA, gyrB, grlA
and grlB genes by PCR
Four sets of oligonucleotides, gyrA1–50-ATGGCT
GAATTACCTCAATC-30 and gyrA2–50-GTGTG-
ATTTTAGTCATACGC-30, grlA1–50-CAGTCGG-
TGATGTTATTGGT-30 and grlA2–50-CCTTGA
ATAATACCACCAGT-30, gyrB1–50-GAAGCTG-
CTACGCATGAA-30 and gyrB2–50-GCTCCATC-
C ICATCGGCATC-30, and grlB1–50-GIGAAGCI-
GCACGTAA-30 and grlB2–50-TCIGTATCIGCA
TCAGTCAT-30, were used to amplify the gyrA,
grlA, gyrB and grlB genes, respectively. Brieﬂy, ﬁve
colonies were resuspended in 300 mL of TE buffer
(100mM Tris-HCl, pH8.0, 100mM EDTA), and 10
units of lysostaphin were added. This bacterial
suspension was incubated at 37 8C for 15min.
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After this, DNA was precipitated with 300 mL of
isopropanol, centrifuged for 15min, washed with
70% ethanol, and ﬁnally resuspended in 100 mL of
sterile water. Two microliters of this suspension
was added to 23 mL of distilled sterile water, and
ﬁnally 25 mL of reaction mixture containing 20mM
Tris-HCl (pH8.8), 100mM potassium chloride,
3mM magnesium chloride, gelatin (0.1 w/v),
400 mM deoxynucleoside triphosphates, 1 mM of
each primer and 2U of Taq polymerase (Gibco,
Life Technologies Inc., Gaithersburg, MD, USA)
were added. Each reaction was overlaid with a
drop of mineral oil, and ampliﬁed with the follow-
ing temperature proﬁles: (1) 30 cycles at 94 8C for
1min, 55 8C for 1min and 72 8C for 1min, for gyrA
and grlA; and (2) 30 cycles at 94 8C for 1min, 50 8C
for 1min and 72 8C for 1min for gyrB and grlB.
The ampliﬁed DNA products were resolved in
2% agarose gel containing 0.5mg/L of ethidium
bromide.
Sequencing of the PCR product
The DNA product obtained from PCR was pur-
iﬁed with the Quiaquick spin PCR puriﬁcation kit
according to the manufacturer’s instructions
(Quiagen Inc., Cathsworth, CA, USA). The sample
was then directly processed for DNA sequencing
using the Taq DyeDeoxiTerminator Cycle Sequen-
cing kit (Perkin Elmer, Foster City, CA, USA) and
analyzed in an automatic DNA sequencer (Abi
Prism 377, Perkin Elmer, Foster City, CA, USA).
Low-frequency restriction analysis of
chromosomal DNA
The DNA preparation for pulsed-ﬁeld gel electro-
phoresis (PFGE) was performed as previously des-
cribed [24] with slight modiﬁcations. Brieﬂy, 20
units of lysostaphin was added in the lysis buffer,
and the incubation of ESP buffer and restriction
mix solution were done overnight. DNA fragments
generated by SmaI were separated by PFGE using
a CHEF-DRII apparatus (Bio-Rad, Richmond, CA,
USA). The pulse times were linearly increased
over 20 h from 5 to 40 s at 200V. Strain S. aureus
NCTC 8325 was used as molecular size DNAmar-
ker, since theDNApatternof this strainwasknown.
Following electrophoresis, the gel was stained with
ethidium bromide and photographed.
To analyze the PFGE patterns, software from
Bio-Rad was used (Diversity Database, Bio-Rad,
Richmond, CA, USA).
RESULTS
Typing of bacterial isolates
The genotyping of S. aureus clinical isolates was
performed by low-frequency restriction analysis of
chromosomal DNA followed by separation of the
DNA fragments by PFGE. MRSA strains showed
greater homogeneity (Figure 1),whileMSSAstrains
showed more heterogeneity (Figure 2).
The 13 MRSA strains could be distributed into
two different clones, clone Awith nine strains, and
Figure 1 Pulsed-field gel electrophoresis and dendrogram of MRSA strains. Lane C, control strain NCTC; lane 1, strain 5-
118; lane 2, strain 4-109; lane 3, strain 5-98; lane 4, strain 4-46; lane 5, strain 5-32; lane 6, strain 4-95; lane 7, strain 4-131; lane
8, strain 4-169; lane 9, strain 4-138; lane 10, strain 4-132; lane 11, strain 5-107; lane 12, strain 5-135; lane 13, strain 5-138.
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clone Bwith the remaining four strains. Themethi-
cillin-susceptible strains showed lower homology,
and seven different clones were observed; one
contained three strains, whereas each of the
remaining strains belonged to a speciﬁc clone. Less
than 0.7 of similarity was considered to indicate
that a strain belonged to another clone.
Antimicrobial susceptibility
Table 1 shows the MICs of ciproﬂoxacin, norﬂox-
acin, sparﬂoxacin, levoﬂoxacin and trovaﬂoxacin,
with and without reserpine, an inhibitor of the
NorA efﬂux pump, and the MIC of oxacillin,
against the 22 S. aureus strains analyzed in this
study. Eight of 22 strains were susceptible to
oxacillin and ciproﬂoxacin, trovaﬂoxacin, levo-
ﬂoxacin. Three of these strains, 4-49, 5-96 and
5-117, were resistant to norﬂoxacin, whereas one
oxacillin-susceptible strain, 4-10, was resistant
to ciproﬂoxacin, norﬂoxacin and sparﬂoxacin,
with MICs of 4mg/L, 32mg/L and 2mg/L,
respectively.
The remaining 13 strains were resistant to oxa-
cillin, ciproﬂoxacin, norﬂoxacin and sparﬂoxacin.
Five of these strains showed susceptibility to levo-
ﬂoxacin (MIC 4mg/L), and the remainder showed
resistance to this antimicrobial agent (MIC ranging
from 8mg/L to 16mg/L). In the case of trovaﬂox-
acin, only four strains, with three mutations, two
in grlA and one in gyrA, showed resistance to this
antimicrobial agent, with MICs ranging from 8 to
32mg/L.
Moreover, the MIC50 and MIC90 of each quino-
lone were calculated, and are shown in Table 2.
Trovaﬂoxacin was at least four-fold more active
than ciproﬂoxacin or levoﬂoxacin and 32-fold
more active than norﬂoxacin. It also had the best
activity in the presence of reserpine.
The MICs of norﬂoxacin and ciproﬂoxacin,
which are hydrophilic quinolones, were decreased
by the presence of reserpine, while trovaﬂoxacin,
levoﬂoxacin and sparﬂoxacin, which are hydro-
phobic quinolones, showed no change in the MIC
values (Table 1). The presence of the activity of
NorA on norﬂoxacin is shown in Table 3. Ten of
22 strains (45.4%), four MSSA and six MRSA,
possessed increased activity of NorA (activity of
NorA was considered when the MIC was reduced
by at least two dilutions), and in the presence of
reserpine their MICs were reduced at least four-
fold.
Detection of gyrA, gyrB, grlA and grlB
mutations by PCR and DNA sequencing
The PCR products from the ampliﬁcation of the
QRDR of the gyrA, gyrB, grlA and grlB genes
Figure 2 Pulsed-field gel electrophoresis and dendrogram of MSSA strains. Lane C, control strain NCTC; lane 1, strain 4-
108; lane 2, strain 5-61; lane 3, strain 4-149; lane 4, strain 5-96; lane 5, strain 4-2; lane 6, strain 4-32; lane 7, strain 4-49; lane 8,
strain 5-117; lane 9, strain 4-10.
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showed the expected sizes of 398 bp, 680 bp,
469 bp, and 363 bp, respectively. The PCR products
were sequenced in order to detect mutations in the
QRDR. The results are shown in Table 4.
Six of 22 strains, all of them MSSA strains, were
susceptible to all the tested quinolones, and did
not present any mutation in the QRDR of the
different targets. TheMICs of ciproﬂoxacin ranged
between 0.006 and 2mg/L, while the MICs of
trovaﬂoxacin were between 0.008 and 0.06mg/
L. Two strains, also MSSA strains, had one muta-
tion at position Ser80 of the grlA gene which
generated a change from Ser to Phe. These strains
hadMICs of ciproﬂoxacin of 1 and 2mg/L, respec-
tively, and MICs of trovaﬂoxacin of 0.06 and
0.12mg/L, respectively. OneMSSA strain and nine
MRSA strains had two mutations, one in the grlA
gene and one in the gyrA gene. The amino acid
change in grlA was the same as that mentioned
above, while in the gyrA gene the mutation was at
position Ser84, producing a change from Ser to
Leu. The MICs of ciproﬂoxacin and trovaﬂoxacin
for these strains ranged from 8 to 64mg/L and
from 1 to 2mg/L, respectively. Finally, the remain-
ing four MRSA strains had three mutations, the
two above-mentioned mutations, plus another
mutation at the amino acid codon Glu84 of the
grlA gene, changing from Glu to Gly in three
Table 1 MICs of different fluoroquinolones against 22 S. aureus clinical isolates
Ciprofloxacin Norfloxacin Sparfloxacin Levofloxacin Trovafloxacin
Strain R þR R þR R þR R þR R þR Oxacillin
MSSA
4-108 0.06 0.03 0.25 0.25 0.03 0.03 0.12 0.12 0.016 0.03 0.25
5-61 0.06 0.03 0.5 0.25 0.016 0.016 0.12 0.06 0.016 0.008 0.25
4-2 0.25 0.12 1 0.5 0.06 0.06 0.25 0.12 0.016 0.016 0.5
4-149 0.25 0.12 2 0.5 0.06 0.06 0.25 0.12 0.06 0.03 0.5
4-32 0.5 0.25 2 1 0.06 0.06 0.25 0.25 0.06 0.06 0.5
5-96 1 1 16 8 0.06 0.06 0.5 0.5 0.06 0.06 0.25
4-49 2 0.5 32 4 0.12 0.06 1 0.5 0.12 0.06 0.5
5-117 1 1 16 4 0.03 0.06 0.5 0.5 0.06 0.12 0.5
4-10 4 2 32 16 2 2 4 2 1 1 0.5
MRSA
5-135 16 16 64 64 8 8 8 8 1 2 256
4-131 16 4 64 16 8 4 8 4 2 1 >256
4-138 8 8 64 32 4 4 4 4 0.5 1 >256
5-107 8 4 64 32 4 4 4 4 2 2 256
4-169 8 8 32 32 4 4 8 8 1 1 >256
5-118 8 4 64 16 4 4 4 4 2 2 8
5-98 16 4 64 16 4 4 4 4 2 1 32
4-132 16 4 64 16 16 16 32 16 8 8 >256
4-109 32 32 128 128 8 16 16 32 32 32 16
5-32 64 32 >512 128 8 8 16 8 1 1 64
5-138 64 32 512 128 16 16 32 32 8 16 >256
4-46 64 16 >512 128 8 8 16 8 2 2 24
4-95 128 128 >512 >512 16 16 32 32 8 8 128
Quinolones were tested in the presence and absence of 25mg/L reserpine (R).
Table 2 MIC50 and MIC90 in the presence and absence of reserpine
Ciprofloxacin Norfloxacin Sparfloxacin Levofloxacin Trovafloxacin
CMI50 8 64 4 4 1
CMI50
a 4 16 4 4 1
CMI90 64 >512 8 16 8
CMI90
a 32 128 16 32 8
aMIC in the presence of 25mg/L of reserpine.
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strains and fromGlu to Lys in the remaining strain.
The MICs of ciproﬂoxacin ranged from 16 to
128mg/L, and the MICs of trovaﬂoxacin ranged
from 8 to 32mg/L.
Mutations in the grlB and the gyrB genes
(Table 4) were found in only ﬁve of 22 strains,
and none could be associated with an increase
in resistance. Two of these strains (strains 5-61
and 4-2) had the same mutations in both genes,
producing a change from Glu317 to Asp in GyrB
and Glu422 to Asp in GrlB; one strain (strain 4-10)
had one mutation in grlB, His478 to Tyr; and the
remaining two strains possessed only one muta-
tion in gyrB (strain 4-131, Leu461 to Phe; and strain
4-46; Glu435 to Gln).
DISCUSSION
S. aureus is the most important Gram-positive
nosocomial pathogen and is also a frequent cause
Table 3 Relationship between the quinolone-resistant mechanism and the MIC of norfloxacin
gyrA grlA Range of norfloxacin
MIC Activity of
No. of
strains S 84 E 88 S 80 E84 gyrB (n) grlB (n) NorA (n) R þR
6 — — — — E317!D(2a) E422!D(2a) þ(2) 4–32 0.5–4
(4) 0.25–2 0.25–1
2 — — F — — — þ(1) 16 4
(1) 16 8
10 L — F — L461! F (1) H478!Y (1) þ(5) 64 to >512 16–128
E435!Q (1) (5) 16–64 16–64
3 L – F G — — þ(2) 64–512 16–128
(1) 128 128
1 L – F K — — (1) >512 512
n, no. of strains.
aThese two strains possessed the same mutations and did not show NorA activity. They do not belong to the same clone.
R, reserpine.
Strain GyrA GyrB GrlA GrlB
MSSA
wt S 84 E 88 — S 80 E 84 —
4–108 – – — – – —
5–61 – – E317(r)¼D – – E422(r)¼D
4–2 – – E317(r)¼D – – E422(r)¼D
4–149 – – — – – —
4–32 – – — – – —
5–96 – – — F – —
4–49 – – — – – —
5–117 – – — F – —
4–10 L – — F – H478(r)Y
MRSA
5–135 L – — F – —
4–131 L – L461(r)F F – —
4–138 L – — F – —
5–107 L – — F – —
4–169 L – — F – —
5–118 L – — F – —
5–98 L – — F – —
4–132 L – — F G —
4–109 L – — F G —
5–32 L – — F – —
5–138 L – — F G —
4–46 L – E435(r)Q F – —
4–95 L – — F K —
Table 4 Amino acid substitutions at
quinolone protein targets
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of nosocomial outbreaks. Resistance of staphylo-
cocci to several antimicrobial agents may contri-
bute to their ability to survive in a hospital
environment and spread among patients,
although there is an alternative view that they
spread because they possess the property of what
has been called epidemigenicity, rather than
because they are antibiotic resistant. This is the
case with MRSA [25–27]. Low-frequency restric-
tion analysis of chromosomal DNA is a powerful
technique frequently used for typing S. aureus.
MSSA strains, in our study, showed genetic het-
erogeneity on analysis with this technique, with a
genetic distance from 0.42 to 0.95, whereas in
MRSA strains only two different clones were
found. Most of the reports about quinolone and
MRSA have described the spread of one or two
clones among ﬁve to eight different clones present
in a hospital, and these epidemic clones of MRSA
have the potential to spread because of resistance
to antibiotics [25–27].
Different quinolones were tested in order to
establish their activity against S. aureus. Older
quinolones like ciproﬂoxacin, norﬂoxacin and
sparﬂoxacin had high levels of resistance—63%,
77% and 63%, respectively—while newer quino-
lones had different activity rates, levoﬂoxacin
showing 40% resistance and trovaﬂoxacin show-
ing the best activity, with only 18% of resistant
strains. When reserpine was added, the resistance
levels of sparﬂoxacin and trovaﬂoxacin were the
same,while thoseoftheotherquinolonesdecreased,
being 59% in the case of ciproﬂoxacin, 63% for nor-
ﬂoxacinand37%forlevoﬂoxacin.Trovaﬂoxacinhad
the best activity against these clinical isolates. It is
interesting to note that all the strainswith anMICof
ciproﬂoxacin plus reserpine 1mg/L presented at
least one amino acid change, although testingmore
strainswithaMICofciproﬂoxacin in thepresenceof
reserpine1mg/L is needed to conﬁrm the useful-
ness of this MIC as a marker of mutations in target
genes.Therefore,whenanS.aureusstrainwithaMIC
of ciproﬂoxacin in thepresence of reserpine1mg/
L is isolated, we can consider that it has at least one
mutation at the amino acid codon Ser80 of the grlA
gene. Thus the probability of the development of a
secondmutationandan increase in theMICover the
breakpoint during treatment with a quinolone
is very high, and thus its use is not recommended
[28].
Nowadays, it is accepted that both DNA gyrase
and topoisomerase IV are the main protein targets
for quinolones [10–13]. Mutational alterations in
the gyrA and the grlA genes encoding the A sub-
units of DNA gyrase and topoisomerase IV,
respectively, have been shown to be the main
mechanism of quinolone resistance acquisition
in a large number of species, including Escherichia
coli [17,29–31]. In S. aureus, the most frequent
substitutions observed were in codons Ser84 and
Glu88 in the gyrA gene, while in the grlA gene the
substitutions were in codons Ser80 and Glu84,
although other changes have been detected
[10,14,17–19]. Recently, several mutations outside
the QRDR of the grlA gene associated with quino-
lone resistance affecting amino acid positions
Arg43, Pro157 and Ala176 have been described
[32]. In our study, amino acid codons Pro157 and
Ala176 were included in the ampliﬁed and
sequenced DNA region, and no mutations were
found in these positions. A fewmutations affecting
the gyrB and grlB genes have also been found to be
associated with quinolone resistance in S. aureus.
In our study, among MSSA, the highest cipro-
ﬂoxacin MIC found was 8mg/L (strain 4-10),
which correlated with a triple mutation in the
gyrA, grlA and grlB genes, even though mutations
in the grlB or gyrB genes do not play an important
role in the acquisition of quinolone resistance.
Among the MRSA, the highest ciproﬂoxacin
MIC found was 128mg/L (strain 4-95), which is
correlated with a triple mutation: Ser84 to Leu in
the gyrA gene and Ser80 to Phe plus Glu84 to Lys in
the grlA gene.
There were two MSSA strains with the same
MIC for ciproﬂoxacin of 1mg/L (strains 5-96 and
5-117) with a mutation in the grlA gene, whereas
another strain (strain 4-49) without mutations had
a higher MIC for ciproﬂoxacin (2mg/L). This
difference could be explained by overexpression
of an efﬂux pump. In fact, when reserpine was
added to determine the MIC of ciproﬂoxacin for
the strain 4-49, it decreased four-fold (0.5mg/L).
The same occurred with norﬂoxacin. Therefore,
this efﬂux pump could be NorA, which confers
resistance to hydrophilic quinolones, such as
norﬂoxacin [20,21]. This is an example of epide-
miologically unrelated strains with different
mechanisms of resistance but with approximately
the same MIC.
On the other hand, epidemiologically related
strains, such as strains 4-46 and 4-95, belonging
to the same clone, but with different mechanisms
of resistance, can be found. The former showed a
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substitution in GyrB (E435 to Q), whereas strain
4-95 did not. However, the latter strain had a sub-
stitution in GrlA (E84 to K) that strain 4-46 did not
have. Furthermore, strain 4-46 showed reduced
ciproﬂoxacin and norﬂoxacin MICs when reser-
pine was added, whereas strain 4-95 did not. The
above-mentioned mutations affected the MIC of
trovaﬂoxacin differently in these strains, the MIC
being higher for strain 4-95. These results suggest
divergent evolution of the same clone associated
with the acquisition of different mechanisms of
quinolone resistance (overexpression of efﬂux
pump or grlA mutations). In Gram-negative bac-
teria, especially E. coli, the ﬁrst step in quinolone
resistance appears to be a mutation in protein
targets, and only bacteria with a high level of
quinolone resistance show enhanced expression
of efﬂux pumps, such as AcrAB [33–35]. However,
a more extensive study in Gram-positive bacteria
is required to ﬁnd whether overexpression of
efﬂux pump or grlA mutations are the ﬁrst step
in quinolone resistance acquisition.
It is interesting to note that the MIC of sparﬂox-
acin did not increase until a mutation in the gyrA
gene appeared. This suggests that, in this case, the
DNA gyrase was the primary target for sparﬂox-
acin, because there were two MSSA strains (5-117
and 5-96) with a mutation in the grlA gene
(Ser80!Phe) with an MIC of sparﬂoxacin below
the breakpoint. Some recent studies have shown
that the primary quinolone protein target could be
changed, depending on the structure or the hydro-
phobicity of quinolones [36].
Among the antimicrobial agents tested, trova-
ﬂoxacin presented the best activity against MSSA
and MRSA strains, even when reserpine was
added, and only the last four strains with three
mutations were resistant to this antimicrobial
agent. These results suggest that trovaﬂoxacin
was not affected by the NorA efﬂux pump.
In our study, it was seen that in over 50% of all
the clinical isolates of S. aureus, the MIC of some
quinolones, such as norﬂoxacin, decreased in the
presence of reserpine. Similar results were found
by Schmitz et al. [37], with about 30% of the
ciproﬂoxacin-resistant strains showing decreased
resistance to ciproﬂoxacin in the presence of reser-
pine. In all cases, the different MICs could be
attributed to the different level of expression of
NorA (studies in progress). Furthermore, in a
previous study with these strains, the norA gene
was analyzed in order to establish the prevalence
of the different sequences encoding this gene [38].
It was seen that the sequence like that described by
Yoshida et al. [20] was more prevalent (18 of 23
strains, 78%) than the sequence described by Kaatz
et al. [21] (ﬁve of 23 strains, 22%). Moreover, efﬂux
systems other than NorA and not inhibited by
reserpine may exist [39], and may explain the
different MICs of trovaﬂoxacin, such as in strains
4-95 and 4-109. These strains had MICs for trova-
ﬂoxacin of 8 and 32mg/L, respectively, and car-
ried the same mutations, two in the grlA gene and
one in the gyrA gene. The MIC of trovaﬂoxacin for
these strains did not decrease in the presence of
reserpine, showing that trovaﬂoxacin is not a sub-
strate for this kind of efﬂux pump, and suggesting
the presence of a non-reserpine-affected efﬂux
pump that can pump trovaﬂoxacin out of the cell,
although mutations outside the QRDR cannot be
ruled out.
The molecular mechanism of overexpression of
the norA gene remains unknown. It has been
suggested that a single mutation in the promoter
region could be responsible [22]. Recently, a new
region upstream from the promoter was described
by Fournier et al. [40] as a regulatory region, where
one unknown protein of 18 kDa could bind and
regulate the transcription of the norA gene by a
two-component regulatory system (ArlS–ArlR).
Therefore, a mutation in a regulatory region or
in the genes coding for these two regulatory pro-
teins may also explain the overexpression of the
norA gene.
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